An Open-label Phase II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza), nivolumab in combination with 5-azacytidine and venetoclax, or Nivolumab with Ipilimumab in combination with 5-azacytidine for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia and newly diagnosed older AML (?65 years) patients
MD Anderson Study Status
Azacitidine, Ipilimumab, Nivolumab
This phase II trial studies the side effects and best dose of nivolumab and azacitidine with or without ipilimumab when given together and to see how well they work in treating patients with acute myeloid leukemia that has not responded to previous treatment or has returned after a period of improvement or is newly diagnosed. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, azacitidine and ipilimumab may kill more cancer cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.